BIRC5 and cervical carcinoma: Recently, Pennati et al. [145] reported that the addition of the novel CDK inhibitor NU6140 to paclitaxel-treated HeLa cervical carcinoma cells resulted in significantly increased cytotoxic effect and apoptotic response in comparison with the paclitaxel-purvalanol A combination, resulting in abrogation of the expression of the survivin active form.